- Home
- ZEO vs ACET Comparison
ZEO vs ACET Comparison
Compare ZEO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- ACET
- Stock Information
- Founded
- ZEO 2005
- ACET 1947
- Country
- ZEO United States
- ACET United States
- Employees
- ZEO N/A
- ACET N/A
- Industry
- ZEO
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- ACET Health Care
- Exchange
- ZEO NYSE
- ACET Nasdaq
- Market Cap
- ZEO 55.5M
- ACET 64.9M
- IPO Year
- ZEO N/A
- ACET N/A
- Fundamental
- Price
- ZEO $2.38
- ACET $0.77
- Analyst Decision
- ZEO
- ACET Buy
- Analyst Count
- ZEO 0
- ACET 6
- Target Price
- ZEO N/A
- ACET $6.00
- AVG Volume (30 Days)
- ZEO 90.1K
- ACET 412.0K
- Earning Date
- ZEO 08-18-2025
- ACET 08-12-2025
- Dividend Yield
- ZEO N/A
- ACET N/A
- EPS Growth
- ZEO N/A
- ACET N/A
- EPS
- ZEO N/A
- ACET N/A
- Revenue
- ZEO $61,885,622.00
- ACET N/A
- Revenue This Year
- ZEO N/A
- ACET N/A
- Revenue Next Year
- ZEO N/A
- ACET N/A
- P/E Ratio
- ZEO N/A
- ACET N/A
- Revenue Growth
- ZEO N/A
- ACET N/A
- 52 Week Low
- ZEO $1.05
- ACET $0.45
- 52 Week High
- ZEO $4.75
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- ZEO 40.30
- ACET 58.16
- Support Level
- ZEO $2.66
- ACET $0.58
- Resistance Level
- ZEO $2.80
- ACET $0.76
- Average True Range (ATR)
- ZEO 0.24
- ACET 0.04
- MACD
- ZEO -0.10
- ACET 0.01
- Stochastic Oscillator
- ZEO 0.00
- ACET 87.50
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy-efficient equipment, and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.